Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2010

View Archived Issues

AF-792, a selective inhibitor of P2X2/3 and P2X3 receptors, regulates bladder activity in rats

Escitalopram prevents relapse in patients with alcoholism and comorbid affective disorders

AstraZeneca reviews Q2 progress

Temsirolimus reduces hypersensitivity in mice with spare nerve injury-induced neuropathic pain

Novel xanthine dehydrogenase/oxidase inhibitors show potent hypouricemic effects in vivo

Representative of new class of SGLT2 inhibitors enters phase II development

Genentech describes selection of novel Chk1 inhibitor for further development

Shionogi and LifeCycle end North American license agreement for Fenoglide

Bioniche and University of Ottawa sign agreement for antianxiety compounds

Chroma Therapeutics advances CHR-5154 into preclinical development

FDA extends review of eribulin NDA for advanced or metastatic breast cancer

Shelf life reduced for Panvax Junior influenza vaccine

Novel PI3K inhibitors claimed by Cellzome

Patient recruitment begins for phase II MK-2206 trial in colorectal cancer

Otsuka identifies new adenosine A2A receptor agonists

Novel antagonists of MCHR-1 presented by sanofi-aventis

Novel FAAH1 inhibitors disclosed by sanofi-aventis

Trius initiates phase III program of torezolid phosphate

FDA extends PDUFA goal date for ezogabine

FDA approves Bionovo's CMC plan for Menerba

FDA issues complete response letter on motavizumab

FDA grants priority review for Iluvien in DME

Kythera and Intendis to develop ATX-101 outside North America

Achaogen awarded contract to develop ACHN-490 and other antibiotics

FDA approves additional strengths of Medicis's Solodyn for acne vulgaris

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...